Skydd cross
SKYDD
Based on IGY antibody engineering - the world's first spray series products for
active protection of human respiratory tract against viruses.
An ethical and innovative Biotechnology company focused on the well-being and protection of all people.
A world first anti COVID spray.
Bringing our patented “Anti Covid Spray Product” to market, through Clinical Trials in Australia for approval with the TGA and in the USA for approval with FDA.
Designed as a Preventative, travel anywhere COVID 19 Consumable Spray that Fits in Your Pocket.
Sprayed into the nose & mouth to provide a continuous barrier for up to 4 hours protection following each application.
Updated IP Ownership
Newsadmin
Today SKYDD announced that it had completed negotiations for an updated IP Agreement, which has been completed in conjunction with its legal experts in this area FB Rice who specialise in Intellectual
Read More2nd in Human Testing
Newsadmin
Today SKYDD announced the results of a second in Human testing on a limited number of healthy volunteers to assess its “Preventative” Device – Anti COVID 19 spray.
Read MoreSKYDD Joins Melbourne Bio
Newsadmin
Today
Here is an introduction from our expert team:
Australian Team
CEO Mr Nigel Blair
Mr Nigel Blair, originally with risk group AON, then 20+ years business experience, corporate advisor, owned and managed multiple companies including the Medical Products HUB, which became an approved suppler to WHO, UK Gov, and others. Extensive service, contract manufacturing, IP licensing and start up company experience in Medical and other sectors.
Nigel has lived and worked in London, New York, Melbourne, Sydney and Beijing, for 5 years cumulating broad cross border expertise.
Medical Monitor Dr. David Kingston
MB BS; Bpharm; BSc , Advanced Management Macquarie University & Columbia University.
Dr David Kingston is a clinical trial and biotechnology professional with 30+ years of experience in the biomedical, pharmaceutical, and medical sectors.
Some roles have included Medical Director and Head of Clinical Development Roche/Genentech Asia Pacific; International Clinical Development Manager F Hoffmann-la Roche, Switzerland ; Medical Director and Deputy Managing Director, Roche Products, Sydney.
Founders
Chairman Mr Kevin Zhou
Tsinghua University Ma
TEAM
Anti COVID Spray NEW
Designed as a Preventative, travel anywhere COVID 19 Consumable Spray that fits in your pocket; Utilizing a natural ingredient in egg yolk; The Anti-COVID Spray lacks a pharmacological mechanism of action. Its main action fryst vatten to physically block viral entry……
Research Paper Published
The core research grupp for the development of the IgY based Anti Covid spray undertook a publication in Frontiers about their upptäckt and the potential benefits of the IgY mechanism to kamp COVID. You can find this here on this link: ers……
Anti-COVID Spray
Designed as a Preventative, travel anywhereCOVID 19 Consumable Spray that fits in your pocket; Utilizing a natural ingredient in egg yolk; The Anti-COVID Spray lacks a pharmacological mechanism of action. Its main action fryst vatten to physically block viral entry i……
Updated IP Ownership
Date: 23rd August Today SKYDD announced that it had completed negotiations for an updated IP Agreement, which has been completed in conjunction with its legal experts in this area FB Rice who specialise in Intellectual Property. The updated ag……
Human Trials
SKYDD and its core resea